InvestorsHub Logo
Followers 17
Posts 4177
Boards Moderated 0
Alias Born 08/20/2004

Re: None

Monday, 07/31/2006 3:41:13 PM

Monday, July 31, 2006 3:41:13 PM

Post# of 146242
Actually, I thought the PR said what NNVC mangement thought aboutthe recent GSK PR and basically explained what the current flu drugs can and cannot do!! And how Fluicde and Aviflucide can do a superior job!

Plus this PR was a shot at the analyst (presumanbly hired by GSK) who put down all the emerging nanomedicine players. Take a look at the PR.....

"...The biotech analyst said the news does not bode well for many of the small biopharmaceutical companies working on their own treatments.

"The GSK data is a significant setback for Novavax and nearly all of the early stage companies that had hoped to parlay the fears of a pandemic into a robust vaccine business," he said."

http://www.forbes.com/2006/07/26/glaxosmithkline-0726markets18.html?partner=yahootix





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News